NCT01721057 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Placebo administered orally (PO) once daily (QD)through Week 24. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
- id
- FG000
- title
- Placebo
- description
- Baricitinib 2 mg PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG001
- title
- Baricitinib 2 mg
- description
- Baricitinib 4 mg PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG002
- title
- Baricitinib 4 mg
- description
- Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG003
- title
- Rescue
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.
- id
- FG004
- title
- Placebo-Follow Up
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.
- id
- FG005
- title
- Baricitinib 2 mg- Follow Up
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug. Includes participants who were rescued to Baricitinib 4 mg.
- id
- FG006
- title
- Baricitinib 4 mg- Follow Up
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 11
- group Id
- FG001
- num Subjects
- 5
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 10
- group Id
- FG002
- num Subjects
- 12
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Death
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 228
- group Id
- FG001
- num Subjects
- 229
- group Id
- FG002
- num Subjects
- 227
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 228
- group Id
- FG001
- num Subjects
- 229
- group Id
- FG002
- num Subjects
- 227
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Received at Least 1 Dose of Study Drug
- achievements
- group Id
- FG000
- num Subjects
- 55
- group Id
- FG001
- num Subjects
- 21
- group Id
- FG002
- num Subjects
- 15
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Rescued
- achievements
- comment
- "Completers" include rescued participants.
- group Id
- FG000
- num Subjects
- 200
- comment
- "Completers" include rescued participants.
- group Id
- FG001
- num Subjects
- 210
- comment
- "Completers" include rescued participants.
- group Id
- FG002
- num Subjects
- 204
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 28
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 23
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lack of Efficacy
- milestones
- achievements
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG000
- num Subjects
- 0
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG001
- num Subjects
- 0
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG002
- num Subjects
- 0
- comment
- Participants who were determined to be nonresponders based on tender/swollen joint count.
- group Id
- FG003
- num Subjects
- 91
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 88
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Rescue Period
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- comment
- Rescued participants who entered post-treatment follow-up are included in Baricitinib 4 mg FollowUp
- group Id
- FG003
- num Subjects
- 0
- comment
- Participants from treatment who entered the post-treatment follow-up period.
- group Id
- FG004
- num Subjects
- 17
- comment
- Participants from treatment who entered the post-treatment follow-up period.
- group Id
- FG005
- num Subjects
- 19
- comment
- Participants from treatment and rescue who entered the post-treatment follow-up period.
- group Id
- FG006
- num Subjects
- 22
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 17
- group Id
- FG005
- num Subjects
- 19
- group Id
- FG006
- num Subjects
- 22
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Follow Up
- pre Assignment Details
- Participants who did not respond (nonresponders) to study drug were eligible for rescue treatment beginning at Week 16. Nonresponders were defined as lack of improvement of at least 20% in both tender joint count and swollen joint count at both Weeks 14 and 16 compared to baseline.
Complete source fields
- groups
- description
- Placebo administered orally (PO) once daily (QD)through Week 24. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
- id
- FG000
- title
- Placebo
- description
- Baricitinib 2 mg PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG001
- title
- Baricitinib 2 mg
- description
- Baricitinib 4 mg PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG002
- title
- Baricitinib 4 mg
- description
- Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.
- id
- FG003
- title
- Rescue
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.
- id
- FG004
- title
- Placebo-Follow Up
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.
- id
- FG005
- title
- Baricitinib 2 mg- Follow Up
- description
- No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug. Includes participants who were rescued to Baricitinib 4 mg.
- id
- FG006
- title
- Baricitinib 4 mg- Follow Up
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 11
- group Id
- FG001
- num Subjects
- 5
- group Id
- FG002
- num Subjects
- 8
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 10
- group Id
- FG002
- num Subjects
- 12
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Death
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 228
- group Id
- FG001
- num Subjects
- 229
- group Id
- FG002
- num Subjects
- 227
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 228
- group Id
- FG001
- num Subjects
- 229
- group Id
- FG002
- num Subjects
- 227
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Received at Least 1 Dose of Study Drug
- achievements
- group Id
- FG000
- num Subjects
- 55
- group Id
- FG001
- num Subjects
- 21
- group Id
- FG002
- num Subjects
- 15
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Rescued
- achievements
- comment
- "Completers" include rescued participants.
- group Id
- FG000
- num Subjects
- 200
- comment
- "Completers" include rescued participants.
- group Id
- FG001
- num Subjects
- 210
- comment
- "Completers" include rescued participants.
- group Id
- FG002
- num Subjects
- 204
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 28
- group Id
- FG001
- num Subjects
- 19
- group Id
- FG002
- num Subjects
- 23
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Treatment Period
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 1
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Adverse Event
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 2
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- Lack of Efficacy
- milestones
- achievements
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG000
- num Subjects
- 0
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG001
- num Subjects
- 0
- comment
- Participants who were nonresponders based on tender/swollen joint count entered into rescue group.
- group Id
- FG002
- num Subjects
- 0
- comment
- Participants who were determined to be nonresponders based on tender/swollen joint count.
- group Id
- FG003
- num Subjects
- 91
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 88
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Rescue Period
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- comment
- Rescued participants who entered post-treatment follow-up are included in Baricitinib 4 mg FollowUp
- group Id
- FG003
- num Subjects
- 0
- comment
- Participants from treatment who entered the post-treatment follow-up period.
- group Id
- FG004
- num Subjects
- 17
- comment
- Participants from treatment who entered the post-treatment follow-up period.
- group Id
- FG005
- num Subjects
- 19
- comment
- Participants from treatment and rescue who entered the post-treatment follow-up period.
- group Id
- FG006
- num Subjects
- 22
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 17
- group Id
- FG005
- num Subjects
- 19
- group Id
- FG006
- num Subjects
- 22
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Follow Up
- pre Assignment Details
- Participants who did not respond (nonresponders) to study drug were eligible for rescue treatment beginning at Week 16. Nonresponders were defined as lack of improvement of at least 20% in both tender joint count and swollen joint count at both Weeks 14 and 16 compared to baseline.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle